Cargando…

A comparison between dexlansoprazole modified release–based and lansoprazole-based nonbismuth quadruple (concomitant) therapy for first-line Helicobacter pylori eradication: a prospective randomized trial

PURPOSE: Steadily maintaining high intra-gastric PH is the major factor for successful Helicobacter pylori (H.pylori) eradication. It is important to search for a stronger PPI. Dexlansoprazole MR is a dual delayed release formulation PPI taken once daily which is capable of maintaining longer durati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tai, Wei-Chen, Liang, Chih-Ming, Bi, Kuo-Wei, Kuo, Chung-Mou, Lu, Lung-Sheng, Wu, Cheng-Kun, Yang, Shih-Cheng, Kuo, Yuan-Hung, Lee, Chen-Hsiang, Huang, Chih-Fang, Hsu, Chien-Ning, Hsu, Pin-I, Wu, Deng-Chyang, Hu, Tsung-Hui, Wu, Keng-Liang, Chuah, Seng-Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6754331/ https://www.ncbi.nlm.nih.gov/pubmed/31571945 http://dx.doi.org/10.2147/IDR.S213998

Ejemplares similares

A Comparison Between Dexlansoprazole Modified Release–Based And Lansoprazole-Based Nonbismuth Quadruple (Concomitant) Therapy For First-Line Helicobacter pylori Eradication: A Prospective Randomized Trial [Corrigendum]
Publicado: (2019)

Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2015)

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice
por: Hung, Kuo-Tung, et al.
Publicado: (2021)

First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease
por: Liang, Chih-Ming, et al.
Publicado: (2017)

Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial
por: Chiang, Hung-Hsien, et al.
Publicado: (2019)

Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication
por: Huang, Hsiang Tso, et al.
Publicado: (2018)

7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan
por: Kao, Sung-Shuo, et al.
Publicado: (2012)

First-line Helicobacter pylori eradication rates are significantly lower in patients with than those without type 2 diabetes mellitus
por: Yao, Chih-Chien, et al.
Publicado: (2019)

The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance
por: Huang, Tzu-Hsin, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Evaluation of Dexlansoprazole Infusion Injection Compared with Lansoprazole in Healthy Chinese Adults
por: Wu, Lihua, et al.
Publicado: (2019)

A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection
por: Wu, Deng-Chyang, et al.
Publicado: (2016)

The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases
por: Wang, Jiunn-Wei, et al.
Publicado: (2016)

Association between Helicobacter pylori eradication and the risk of coronary heart diseases
por: Wang, Jiunn-Wei, et al.
Publicado: (2018)

First-Line Helicobacter pylori Eradication in Patients with Chronic Kidney Diseases in Taiwan
por: Liang, Chih-Ming, et al.
Publicado: (2017)

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections
por: Kuo, Chia-Jung, et al.
Publicado: (2019)

The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole
por: Peura, D A, et al.
Publicado: (2013)

Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
por: Huh, Ki Young, et al.
Publicado: (2021)

The Clinical and Bacteriological Factors for Optimal Levofloxacin-Containing Triple Therapy in Second-Line Helicobacter pylori Eradication
por: Tai, Wei-Chen, et al.
Publicado: (2014)

A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication
por: Chuah, Seng-Kee, et al.
Publicado: (2016)

The efficacy of limited endoscopic sphincterotomy plus endoscopic papillary large balloon dilation for removal of large bile duct stones
por: Kuo, Chung-Mou, et al.
Publicado: (2019)

Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan
por: Tai, Wei-Chen, et al.
Publicado: (2013)

Predicting risk factors for rebleeding, infections, mortality following peptic ulcer bleeding in patients with cirrhosis and the impact of antibiotics prophylaxis at different clinical stages of the disease
por: Kuo, Ming-Te, et al.
Publicado: (2015)

Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for Helicobacter pylori eradication: A prospective open-label randomized trial
por: Kim, So Jeong, et al.
Publicado: (2019)

Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
por: Jheng, Guang-Hong, et al.
Publicado: (2015)

Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori
por: Gisbert, Javier P, et al.
Publicado: (2012)

Risk of Rebleeding and Mortality in Cirrhotic Patients with Peptic Ulcer Bleeding: A 12-Year Nationwide Cohort Study
por: Yang, Shih-Cheng, et al.
Publicado: (2017)

The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation
por: Wu, Cheng-Kun, et al.
Publicado: (2017)

Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study
por: Liang, Chih-Ming, et al.
Publicado: (2016)

Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan
por: Liang, Chih-Ming, et al.
Publicado: (2020)

Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis
por: Yuan, Lan-Ting, et al.
Publicado: (2018)

Treatment and Cost of Hepatocellular Carcinoma: A Population-Based Cohort Study in Taiwan
por: Nguang, Seng-Howe, et al.
Publicado: (2018)

Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan
por: Hung, Tsung-Hsing, et al.
Publicado: (2017)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Limited precut sphincterotomy combined with endoscopic papillary balloon dilation for common bile duct stone removal in patients with difficult biliary cannulation
por: Kuo, Chung-Mou, et al.
Publicado: (2016)

Quinolone-Containing Therapies in the Eradication of Helicobacter pylori
por: Chuah, Seng-Kee, et al.
Publicado: (2014)

Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
por: Ashida, Kiyoshi, et al.
Publicado: (2018)

Zinc carnosine-based modified bismuth quadruple therapy vs standard triple therapy for Helicobacter pylori eradication: A randomized controlled study
por: Ibrahim, Nour, et al.
Publicado: (2022)

Synergistic Effect of Metformin and Lansoprazole Against Gastric Cancer through Growth Inhibition
por: Kao, Hsiao-Wei, et al.
Publicado: (2023)

Outcome of Holiday and Nonholiday Admission Patients with Acute Peptic Ulcer Bleeding: A Real-World Report from Southern Taiwan
por: Wu, Tsung-Chin, et al.
Publicado: (2014)

A comparison between non-sedation and general endotracheal anesthesia for retrograde endoscopic common bile duct stone removal: A tertiary center experience
por: Liang, Chih-Ming, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nfhm6bqdpulr9qesqbd75s2bt4